GlassScriptPhysician profile
Gina Kim
NPI 1629415880
$3,878.41
in general payments reported to CMS, 2019-2025
26 companies · $32.53 in 2025
The $32.53 reported for 2025 was less than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $939 · 2022: $1,242 · 2023: $959 · 2024: $705 · 2025: $32.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,697.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $499.28 | 2021-2024 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $487.34 | 2021-2024 | |
| Amgen INC. | $472.29 | 2021-2024 | Repatha, Otezla, Tezspire |
| Abbvie INC. | $309.45 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $292.13 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $228.01 | 2021-2024 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.50 | 2021-2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $162.70 | 2023-2024 | Rexulti, Nuedexta |
| Abbott Laboratories | $158.58 | 2022-2023 | Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $146.79 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $122.92 | 2021-2023 | |
| Esperion Therapeutics, INC. | $112.88 | 2021-2023 | Nexletol |
| Avanir Pharmaceuticals, INC. | $93.28 | 2021 | |
| Novartis Pharmaceuticals Corporation | $88.25 | 2022 | |
| Exact Sciences Corporation | $81.02 | 2023-2024 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $77.42 | 2022-2023 | Gvoke Hypopen |
| Amarin Pharma, INC. | $63.33 | 2021 | |
| Sumitomo Pharma America, INC. | $47.57 | 2023 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $42.40 | 2021-2022 | |
| Baxter Healthcare | $42.19 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.81 | 2021-2023 | Tradjenta, Jardiance |
| Actelion Pharmaceuticals US, INC. | $37.00 | 2024 | Opsumit |
| Inspire Medical Systems, INC. | $32.53 | 2025 | Inspire |
| Genzyme Corporation | $28.02 | 2024 | |
| Pfizer INC. | $16.63 | 2021 | |
| Dexcom, INC. | $14.09 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.